First Header Logo Second Header Logo

Connection

Karl-Erik Andersson to Humans

Back to Details
This is a "connection" page, showing publications Karl-Erik Andersson has written about Humans.
Karl-Erik Andersson
Connection Strength
2.323
Humans
  1. Bennington J, Williams JK, Andersson KE. New concepts in regenerative medicine approaches to the treatment of female stress urinary incontinence. Curr Opin Urol. 2019 07; 29(4):380-384.
    View in: PubMed
    Score: 0.033
  2. Andersson KE. Oxidative stress and lower urinary tract symptoms: cause or consequence? BJU Int. 2019 05; 123(5):749-750.
    View in: PubMed
    Score: 0.032
  3. Andersson KE, Longstreth J, Brucker BM, Campeau L, Cheng L, Francis L, Fein S. Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. Pharm Res. 2019 Apr 29; 36(6):92.
    View in: PubMed
    Score: 0.032
  4. Fry CH, Kitney DG, Paniker J, Drake MJ, Kanai A, Andersson KE. Fibrosis and the bladder, implications for function ICI-RS 2017. Neurourol Urodyn. 2018 06; 37(S4):S7-S12.
    View in: PubMed
    Score: 0.030
  5. Andersson KE, Fry C, Panicker J, Rademakers K. Which molecular targets do we need to focus on to improve lower urinary tract dysfunction? ICI-RS 2017. Neurourol Urodyn. 2018 06; 37(S4):S117-S126.
    View in: PubMed
    Score: 0.030
  6. Andersson KE, Van Kerrebroeck P. Pharmacotherapy for Nocturia. Curr Urol Rep. 2018 Feb 09; 19(1):8.
    View in: PubMed
    Score: 0.030
  7. Andersson KE. Oxidative stress and its possible relation to lower urinary tract functional pathology. BJU Int. 2018 04; 121(4):527-533.
    View in: PubMed
    Score: 0.029
  8. Andersson KE. Pharmacology: Cardiovascular effects of mirabegron. Nat Rev Urol. 2017 10; 14(10):587-588.
    View in: PubMed
    Score: 0.029
  9. Andersson KE. Re: Inhibition of Cholinergic Neurotransmission by ß3-adrenoceptors Depends on Adenosine Release and A1 Receptors Activation in Human and Rat Urinary Bladders. Eur Urol. 2017 10; 72(4):650-651.
    View in: PubMed
    Score: 0.028
  10. Andersson KE, Williams JK. Regenerative pharmacology in urology. Investig Clin Urol. 2017 03; 58(2):79-81.
    View in: PubMed
    Score: 0.028
  11. Williams JK, Dean A, Lankford S, Criswell T, Badlani G, Andersson KE. Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency. Stem Cell Res Ther. 2017 01 06; 8(1):1.
    View in: PubMed
    Score: 0.028
  12. Williams JK, Andersson KE. Regenerative pharmacology: recent developments and future perspectives. Regen Med. 2016 12; 11(8):859-870.
    View in: PubMed
    Score: 0.027
  13. Simonsen U, Comerma-Steffensen S, Andersson KE. Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction. Basic Clin Pharmacol Toxicol. 2016 Oct; 119 Suppl 3:63-74.
    View in: PubMed
    Score: 0.027
  14. Andersson KE. Re: Nonantimuscarinic Treatment for Overactive Bladder: A Systematic Review. Eur Urol. 2016 12; 70(6):1077.
    View in: PubMed
    Score: 0.027
  15. Williams JK, Dean A, Badlani G, Andersson KE. Regenerative Medicine Therapies for Stress Urinary Incontinence. J Urol. 2016 12; 196(6):1619-1626.
    View in: PubMed
    Score: 0.027
  16. Andersson KE. Potential Future Pharmacological Treatment of Bladder Dysfunction. Basic Clin Pharmacol Toxicol. 2016 Oct; 119 Suppl 3:75-85.
    View in: PubMed
    Score: 0.026
  17. Sawada N, Nomiya M, Zarifpour M, Mitsui T, Takeda M, Andersson KE. Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia. J Sex Med. 2016 Feb; 13(2):179-86.
    View in: PubMed
    Score: 0.026
  18. Andersson KE. Pharmacology: On the mode of action of mirabegron. Nat Rev Urol. 2016 Mar; 13(3):131-2.
    View in: PubMed
    Score: 0.026
  19. Andersson KE. Drug therapy of overactive bladder--what is coming next? Korean J Urol. 2015 Oct; 56(10):673-9.
    View in: PubMed
    Score: 0.025
  20. Kullmann FA, Birder LA, Andersson KE. Translational Research and Functional Changes in Voiding Function in Older Adults. Clin Geriatr Med. 2015 Nov; 31(4):535-48.
    View in: PubMed
    Score: 0.025
  21. Andersson KE. Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol. 2015 Jan; 25(1):12-8.
    View in: PubMed
    Score: 0.024
  22. Andersson KE, Nomiya M, Yamaguchi O. Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (LUTS): A New Target for Pharmacological Treatment? Low Urin Tract Symptoms. 2015 Jan; 7(1):1-8.
    View in: PubMed
    Score: 0.024
  23. Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014 Nov; 24(6):571-7.
    View in: PubMed
    Score: 0.024
  24. Andersson KE. Potential of stem cell treatment in detrusor dysfunction. Adv Drug Deliv Rev. 2015 Mar; 82-83:117-22.
    View in: PubMed
    Score: 0.024
  25. Andersson KE. Words of wisdom. Re: Tissue engineering of the bladder: reality or myth? A systematic review. Eur Urol. 2014 Sep; 66(3):593.
    View in: PubMed
    Score: 0.023
  26. Andersson KE. The many faces of impaired bladder emptying. Curr Opin Urol. 2014 Jul; 24(4):363-9.
    View in: PubMed
    Score: 0.023
  27. Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014 Apr; 33 Suppl 1:S2-5.
    View in: PubMed
    Score: 0.023
  28. Gedda L, Björkelund H, Lebel L, Asplund A, Dubois L, Wester K, Penagos N, Malmqvist M, Andersson K. Evaluation of real-time immunohistochemistry and interaction map as an alternative objective assessment of HER2 expression in human breast cancer tissue. Appl Immunohistochem Mol Morphol. 2013 Dec; 21(6):497-505.
    View in: PubMed
    Score: 0.022
  29. Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol Urodyn. 2014 Jan; 33(1):54-8.
    View in: PubMed
    Score: 0.022
  30. Andersson KE. Bladder underactivity. Eur Urol. 2014 Feb; 65(2):399-401.
    View in: PubMed
    Score: 0.022
  31. Andersson KE. ß3-receptor agonists for overactive bladder--new frontier or more of the same? Curr Urol Rep. 2013 Oct; 14(5):435-41.
    View in: PubMed
    Score: 0.022
  32. Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? Neurourol Urodyn. 2014 Jan; 33(1):9-16.
    View in: PubMed
    Score: 0.022
  33. Christ GJ, Saul JM, Furth ME, Andersson KE. The pharmacology of regenerative medicine. Pharmacol Rev. 2013 Jul; 65(3):1091-133.
    View in: PubMed
    Score: 0.022
  34. Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013 Apr; 93(2):653-80.
    View in: PubMed
    Score: 0.021
  35. Andersson KE, Martin N, Nitti V. Selective ß3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013 Oct; 190(4):1173-80.
    View in: PubMed
    Score: 0.021
  36. Andersson KE. Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol. 2013 Apr; 47(2):83-90.
    View in: PubMed
    Score: 0.021
  37. Ishizuka O, Imamura T, Kurizaki Y, Nishizawa O, Andersson KE. Male lower urinary tract symptoms and a1D-adrenoceptors. Int J Urol. 2013 Jan; 20(1):73-8.
    View in: PubMed
    Score: 0.021
  38. Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Int J Urol. 2013 Jan; 20(1):21-7.
    View in: PubMed
    Score: 0.021
  39. Gratzke C, Andersson KE. a-Blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on. Eur Urol. 2013 Jan; 63(1):166-7; discussion 168.
    View in: PubMed
    Score: 0.020
  40. Andersson KE. Drugs for lower urinary tract symptoms--anything new? J Urol. 2012 Aug; 188(2):349-50.
    View in: PubMed
    Score: 0.020
  41. Kurizaki Y, Ishizuka O, Imamura T, Ishikawa M, Ichino M, Ogawa T, Nishizawa O, Andersson KE. Relationship between expression of ß3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013 Jan; 32(1):88-91.
    View in: PubMed
    Score: 0.020
  42. Soler R, Füllhase C, Hanson A, Campeau L, Santos C, Andersson KE. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol. 2012 Apr; 187(4):1491-7.
    View in: PubMed
    Score: 0.020
  43. Campeau L, Soler R, Andersson KE. Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep. 2011 Dec; 12(6):396-403.
    View in: PubMed
    Score: 0.019
  44. Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²5I-EGF. PLoS One. 2011; 6(9):e24739.
    View in: PubMed
    Score: 0.019
  45. Andersson KE. Neurourology and Urodynamics. Editorial. Neurourol Urodyn. 2011 Sep; 30(7):1207.
    View in: PubMed
    Score: 0.019
  46. Campeau L, Gorbachinsky I, Badlani GH, Andersson KE. Pelvic floor disorders: linking genetic risk factors to biochemical changes. BJU Int. 2011 Oct; 108(8):1240-7.
    View in: PubMed
    Score: 0.019
  47. Andersson KE, Abdel-Hamid IA. Therapeutic targets for premature ejaculation. Maturitas. 2011 Sep; 70(1):26-33.
    View in: PubMed
    Score: 0.019
  48. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011 Aug; 72(2):186-96.
    View in: PubMed
    Score: 0.019
  49. Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 2012 Feb; 109(4):572-80.
    View in: PubMed
    Score: 0.019
  50. Andersson KE, Soler R, Füllhase C. Rodent models for urodynamic investigation. Neurourol Urodyn. 2011 Jun; 30(5):636-46.
    View in: PubMed
    Score: 0.019
  51. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011 Mar; 30(3):292-301.
    View in: PubMed
    Score: 0.018
  52. Björkelund H, Gedda L, Andersson K. Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context. PLoS One. 2011 Jan 31; 6(1):e16536.
    View in: PubMed
    Score: 0.018
  53. Björkelund H, Gedda L, Andersson K. Avoiding false negative results in specificity analysis of protein-protein interactions. J Mol Recognit. 2011 Jan-Feb; 24(1):81-9.
    View in: PubMed
    Score: 0.018
  54. Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011 Mar; 59(3):377-86.
    View in: PubMed
    Score: 0.018
  55. Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson KE. Relation between expression of a(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011 Feb; 45(1):15-9.
    View in: PubMed
    Score: 0.018
  56. Andersson KE, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010 Oct; 106(8):1114-27.
    View in: PubMed
    Score: 0.018
  57. Andersson KE. Detrusor underactivity/underactive bladder: new research initiatives needed. J Urol. 2010 Nov; 184(5):1829-30.
    View in: PubMed
    Score: 0.018
  58. Gedda L, Björkelund H, Andersson K. Real-time immunohistochemistry analysis of embedded tissue. Appl Radiat Isot. 2010 Dec; 68(12):2372-6.
    View in: PubMed
    Score: 0.018
  59. Kanai A, Andersson KE. Bladder afferent signaling: recent findings. J Urol. 2010 Apr; 183(4):1288-95.
    View in: PubMed
    Score: 0.017
  60. Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010; 29(1):97-106.
    View in: PubMed
    Score: 0.017
  61. Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010 Jul; 106(2):268-74.
    View in: PubMed
    Score: 0.017
  62. Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009 Oct; 8(42):118-24.
    View in: PubMed
    Score: 0.017
  63. Abdel-Hamid IA, Andersson KE. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. Pharmacogenomics. 2009 Oct; 10(10):1625-44.
    View in: PubMed
    Score: 0.017
  64. Andersson KE. Prostanoid receptor subtypes: new targets for OAB drugs? J Urol. 2009 Nov; 182(5):2099-100.
    View in: PubMed
    Score: 0.017
  65. Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, Roehrborn CG, Stief CG, Andersson KE. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009 Nov; 56(5):810-9.
    View in: PubMed
    Score: 0.017
  66. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009 Jul; 19(4):380-94.
    View in: PubMed
    Score: 0.016
  67. Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P, Andersson KE. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol. 2009 Apr; 181(4):1939-48.
    View in: PubMed
    Score: 0.016
  68. Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets. 2009 Feb; 13(2):175-93.
    View in: PubMed
    Score: 0.016
  69. Andersson KE, Fullhase C, Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008 Nov; 9(6):459-64.
    View in: PubMed
    Score: 0.016
  70. Andersson KE. Are female lower urinary tract symptoms alleviated by alpha-adrenoreceptor antagonists? Nat Clin Pract Urol. 2008 Nov; 5(11):586-7.
    View in: PubMed
    Score: 0.016
  71. Andersson KE. How many drugs for LUTS due to BPH are too many? J Urol. 2008 Sep; 180(3):811-2.
    View in: PubMed
    Score: 0.015
  72. Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int. 2008 Sep; 102(6):741-6.
    View in: PubMed
    Score: 0.015
  73. Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008 Apr; 101(8):1036-42.
    View in: PubMed
    Score: 0.015
  74. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007 Nov; 100(5):987-1006.
    View in: PubMed
    Score: 0.015
  75. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007 Nov; 100(5):1007-14.
    View in: PubMed
    Score: 0.015
  76. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007 Oct; 26(6 Suppl):948-54.
    View in: PubMed
    Score: 0.015
  77. Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007 Oct; 26(6 Suppl):928-33.
    View in: PubMed
    Score: 0.015
  78. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007 Jul; 4(7):368-78.
    View in: PubMed
    Score: 0.014
  79. Andersson KE, Christ GJ. Regenerative pharmacology: the future is now. Mol Interv. 2007 Apr; 7(2):79-86.
    View in: PubMed
    Score: 0.014
  80. Sjöqvist F, Eriksson LO, Andersson KE. Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden. Eur J Clin Pharmacol. 2007 Mar; 63(3):229-31.
    View in: PubMed
    Score: 0.014
  81. Björke H, Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot. 2006 Aug; 64(8):901-5.
    View in: PubMed
    Score: 0.013
  82. Andersson KE, Mulhall JP, Wyllie MG. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. BJU Int. 2006 Feb; 97(2):311-5.
    View in: PubMed
    Score: 0.013
  83. Andersson KE. Tachykinins: role in detrusor overactivity? Eur Urol. 2006 Mar; 49(3):423-5.
    View in: PubMed
    Score: 0.013
  84. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004 Dec; 56(4):581-631.
    View in: PubMed
    Score: 0.012
  85. Andersson KE. Mechanisms of Disease: central nervous system involvement in overactive bladder syndrome. Nat Clin Pract Urol. 2004 Dec; 1(2):103-8.
    View in: PubMed
    Score: 0.012
  86. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004 Jul; 84(3):935-86.
    View in: PubMed
    Score: 0.012
  87. Andersson KE. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004 Mar; 63(3 Suppl 1):32-41.
    View in: PubMed
    Score: 0.011
  88. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004 Jan; 3(1):46-53.
    View in: PubMed
    Score: 0.011
  89. Andersson KE. Detrusor contraction--Focus on muscarinic receptors. Scand J Urol Nephrol Suppl. 2004; (215):54-7.
    View in: PubMed
    Score: 0.011
  90. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003 Nov; 62(5 Suppl 2):3-10.
    View in: PubMed
    Score: 0.011
  91. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol. 2003 Aug; 170(2 Pt 2):S6-13; discussion S13-4.
    View in: PubMed
    Score: 0.011
  92. Ho KM, Borja MC, Persson K, Brading AF, Andersson KE. Expression of nitric oxide synthase immunoreactivity in the human female intramural striated urethral sphincter. J Urol. 2003 Jun; 169(6):2407-11.
    View in: PubMed
    Score: 0.011
  93. Andersson KE, Pehrson R. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs. 2003; 63(23):2595-611.
    View in: PubMed
    Score: 0.010
  94. Christ GJ, Venkateswarlu K, Day NS, Valcic M, Santizo C, Zhao W, Wang HZ, Persson K, Andersson KE. Intercellular communication and bladder function. Adv Exp Med Biol. 2003; 539(Pt A):239-54.
    View in: PubMed
    Score: 0.010
  95. Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology. 2002 Nov; 60(5 Suppl 1):13-20; discussion 20-1.
    View in: PubMed
    Score: 0.010
  96. Andersson KE. Treatment of the overactive bladder: possible central nervous system drug targets. Urology. 2002 May; 59(5 Suppl 1):18-24.
    View in: PubMed
    Score: 0.010
  97. Andersson KE. Bladder activation: afferent mechanisms. Urology. 2002 May; 59(5 Suppl 1):43-50.
    View in: PubMed
    Score: 0.010
  98. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002 Apr; 19(6):390-6.
    View in: PubMed
    Score: 0.010
  99. Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002 Apr; 19(6):397-404.
    View in: PubMed
    Score: 0.010
  100. Andersson KE, Chapple CR, Höfner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol. 2002 Apr; 19(6):436-42.
    View in: PubMed
    Score: 0.010
  101. Sievert KD, Hennenlotter J, Dillenburg T, Toomey P, Wöllner J, Zweers P, Pannek J, Andersson KE, Amend B. Extended periprostatic nerve distributions on the prostate surface confirmed using diffusion tensor imaging. BJU Int. 2019 06; 123(6):995-1004.
    View in: PubMed
    Score: 0.008
  102. Kira S, Mitsui T, Miyamoto T, Ihara T, Nakagomi H, Hashimoto Y, Takamatsu H, Tanahashi M, Takeda M, Sawada N, Andersson KE, Takeda M. Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men. World J Urol. 2019 Oct; 37(10):2199-2205.
    View in: PubMed
    Score: 0.008
  103. Serati M, Andersson KE, Dmochowski R, Agrò EF, Heesakkers J, Iacovelli V, Novara G, Khullar V, Chapple C. Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. Eur Urol. 2019 01; 75(1):129-168.
    View in: PubMed
    Score: 0.008
  104. Lombardo R, Andersson KE, Tubaro A, De Nunzio C. Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urol Nefrol. 2018 Dec; 70(6):570-578.
    View in: PubMed
    Score: 0.008
  105. Butler DSC, Ambite I, Nagy K, Cafaro C, Ahmed A, Nadeem A, Filenko N, Tran TH, Andersson KE, Wullt B, Puthia M, Svanborg C. Neuroepithelial control of mucosal inflammation in acute cystitis. Sci Rep. 2018 07 20; 8(1):11015.
    View in: PubMed
    Score: 0.008
  106. Hämäläinen MD, Zetterström A, Winkvist M, Söderquist M, Karlberg E, Öhagen P, Andersson K, Nyberg F. Real-time Monitoring using a breathalyzer-based eHealth system can identify lapse/relapse patterns in alcohol use disorder Patients. Alcohol Alcohol. 2018 Jul 01; 53(4):368-375.
    View in: PubMed
    Score: 0.008
  107. Eberli D, Horst M, Mortezavi A, Andersson KE, Gobet R, Sulser T, Simon HU, Salemi S. Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018 11; 37(8):2414-2424.
    View in: PubMed
    Score: 0.008
  108. Colaco M, Osman NI, Karakeçi A, Artibani W, Andersson KE, Badlani GH. Current concepts of the acontractile bladder. BJU Int. 2018 08; 122(2):195-202.
    View in: PubMed
    Score: 0.008
  109. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017 10; 3(4-5):352-363.
    View in: PubMed
    Score: 0.007
  110. Vahabi B, Wagg AS, Rosier PFWM, Rademakers KLJ, Denys MA, Pontari M, Lovick T, Valentini FA, Nelson PP, Andersson KE, Fry CH. Can we define and characterize the aging lower urinary tract?-ICI-RS 2015. Neurourol Urodyn. 2017 04; 36(4):854-858.
    View in: PubMed
    Score: 0.007
  111. Riemsma R, Hagen S, Kirschner-Hermanns R, Norton C, Wijk H, Andersson KE, Chapple C, Spinks J, Wagg A, Hutt E, Misso K, Deshpande S, Kleijnen J, Milsom I. Can incontinence be cured? A systematic review of cure rates. BMC Med. 2017 03 24; 15(1):63.
    View in: PubMed
    Score: 0.007
  112. Lin WY, Andersson KE, Lin CL, Kao CH, Wu HC. Association of lower urinary tract syndrome with peripheral arterial occlusive disease. PLoS One. 2017; 12(3):e0170288.
    View in: PubMed
    Score: 0.007
  113. Walker SJ, Zambon J, Andersson KE, Langefeld CD, Matthews CA, Badlani G, Bowman H, Evans RJ. Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2017 08; 198(2):369-375.
    View in: PubMed
    Score: 0.007
  114. Kallner HK, Elmér C, Andersson KE, Altman D. Hormonal influence on the effect of mirabegron treatment for overactive bladder. Menopause. 2016 12; 23(12):1303-1306.
    View in: PubMed
    Score: 0.007
  115. Hillerdal V, Boura VF, Björkelund H, Andersson K, Essand M. Avidity characterization of genetically engineered T-cells with novel and established approaches. BMC Immunol. 2016 07 13; 17(1):23.
    View in: PubMed
    Score: 0.007
  116. Abdel-Hamid IA, Andersson KE, Waldinger MD, Anis TH. Tramadol Abuse and Sexual Function. Sex Med Rev. 2016 07; 4(3):235-246.
    View in: PubMed
    Score: 0.007
  117. Kirschner-Hermanns R, Anding R, Rosier P, Birder L, Andersson KE, Djurhuus JC. Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction--ICI-RS 2014. Neurourol Urodyn. 2016 Feb; 35(2):318-23.
    View in: PubMed
    Score: 0.006
  118. Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2016 07; 70(1):124-133.
    View in: PubMed
    Score: 0.006
  119. Broegger T, Andersson KE, Aalkjaer C, Forman A, Boedtkjer DB. Sensitivity to the thromboxane A2 analog U46619 varies with inner diameter in human stem villous arteries. Placenta. 2016 Mar; 39:111-5.
    View in: PubMed
    Score: 0.006
  120. Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS One. 2016; 11(1):e0145545.
    View in: PubMed
    Score: 0.006
  121. Peess C, von Proff L, Goller S, Andersson K, Gerg M, Malmqvist M, Bossenmaier B, Schräml M. Deciphering the stepwise binding mode of HRG1ß to HER3 by surface plasmon resonance and interaction map. PLoS One. 2015; 10(2):e0116870.
    View in: PubMed
    Score: 0.006
  122. Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015 Jan; 22(1):40-6.
    View in: PubMed
    Score: 0.006
  123. Bondza S, Stenberg J, Nestor M, Andersson K, Björkelund H. Conjugation effects on antibody-drug conjugates: evaluation of interaction kinetics in real time on living cells. Mol Pharm. 2014 Nov 03; 11(11):4154-63.
    View in: PubMed
    Score: 0.006
  124. Peng Z, Andersson K, Lindholm J, Bodin I, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS One. 2014; 9(10):e109610.
    View in: PubMed
    Score: 0.006
  125. Drumm BT, Koh SD, Andersson KE, Ward SM. Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. Nat Rev Urol. 2014 Oct; 11(10):555-64.
    View in: PubMed
    Score: 0.006
  126. Kunit T, Gratzke C, Schreiber A, Strittmatter F, Waidelich R, Rutz B, Loidl W, Andersson KE, Stief CG, Hennenberg M. Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. Am J Physiol Renal Physiol. 2014 Oct 01; 307(7):F823-32.
    View in: PubMed
    Score: 0.006
  127. Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE, Walker SJ. Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. J Urol. 2014 Oct; 192(4):1123-9.
    View in: PubMed
    Score: 0.006
  128. Birder LA, Andersson KE, Kanai AJ, Hanna-Mitchell AT, Fry CH. Urothelial mucosal signaling and the overactive bladder-ICI-RS 2013. Neurourol Urodyn. 2014 Jun; 33(5):597-601.
    View in: PubMed
    Score: 0.006
  129. Dubois L, Andersson K, Asplund A, Björkelund H. Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods. BMC Res Notes. 2013 Dec 18; 6:542.
    View in: PubMed
    Score: 0.006
  130. Xu B, Varasteh Z, Orlova A, Andersson K, Larhammar D, Björkelund H. Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochem Biophys Res Commun. 2013 Nov 29; 441(4):820-4.
    View in: PubMed
    Score: 0.006
  131. Hennenberg M, Miljak M, Herrmann D, Strittmatter F, Walther S, Rutz B, Hocaoglu Y, Kunit T, Schreiber A, Andersson KE, Stief CG, Gratzke C. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol. 2013 Nov 15; 305(10):F1383-90.
    View in: PubMed
    Score: 0.005
  132. Soler R, Andersson KE, Chancellor MB, Chapple CR, de Groat WC, Drake MJ, Gratzke C, Lee R, Cruz F. Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013 Oct; 64(4):610-21.
    View in: PubMed
    Score: 0.005
  133. Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm. 2013 Apr; 28(3):187-95.
    View in: PubMed
    Score: 0.005
  134. Svalø J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P. The novel ß3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol. 2013 Jan 15; 699(1-3):101-5.
    View in: PubMed
    Score: 0.005
  135. Hennenberg M, Strittmatter F, Beckmann C, Rutz B, Füllhase C, Waidelich R, Montorsi F, Hedlund P, Andersson KE, Stief CG, Gratzke C. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS One. 2012; 7(11):e50904.
    View in: PubMed
    Score: 0.005
  136. Orlova A, Hofström C, Strand J, Varasteh Z, Sandstrom M, Andersson K, Tolmachev V, Gräslund T. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging. 2013 Feb; 40(3):439-49.
    View in: PubMed
    Score: 0.005
  137. Hicks AN, Lorenzetti D, Gilley J, Lu B, Andersson KE, Miligan C, Overbeek PA, Oppenheim R, Bishop CE. Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS One. 2012; 7(10):e47869.
    View in: PubMed
    Score: 0.005
  138. Peyton CC, Burmeister D, Petersen B, Andersson KE, Christ G. Characterization of the early proliferative response of the rodent bladder to subtotal cystectomy: a unique model of mammalian organ regeneration. PLoS One. 2012; 7(10):e47414.
    View in: PubMed
    Score: 0.005
  139. Ekerljung L, Wållberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Ståhl S, Gedda L. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem. 2012 Sep 19; 23(9):1802-11.
    View in: PubMed
    Score: 0.005
  140. Malykhina AP, Wyndaele JJ, Andersson KE, De Wachter S, Dmochowski RR. Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn. 2012 Mar; 31(3):352-8.
    View in: PubMed
    Score: 0.005
  141. Bharadwaj S, Liu G, Shi Y, Markert C, Andersson KE, Atala A, Zhang Y. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A. 2011 Aug; 17(15-16):2123-32.
    View in: PubMed
    Score: 0.005
  142. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011 Oct; 60(4):784-95.
    View in: PubMed
    Score: 0.005
  143. Kanai A, Wyndaele JJ, Andersson KE, Fry C, Ikeda Y, Zabbarova I, De Wachter S. Researching bladder afferents-determining the effects of ß(3) -adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn. 2011 Jun; 30(5):684-91.
    View in: PubMed
    Score: 0.005
  144. Hennenberg M, Strittmatter F, Walther S, Hedlund P, Andersson KE, Stief CG, Schlenker B, Gratzke C. a1-adrenoceptor activation induces phosphorylation of ß2-adrenoceptors in human prostate tissue. BJU Int. 2011 Sep; 108(6):922-8.
    View in: PubMed
    Score: 0.005
  145. Bauer RM, Strittmatter F, Gratzke C, Göttinger J, Schlenker B, Reich O, Stief CG, Hedlund P, Andersson KE, Hennenberg M. Coupling of a1-adrenoceptors to ERK1/2 in the human prostate. Urol Int. 2011; 86(4):427-33.
    View in: PubMed
    Score: 0.005
  146. Nielsen JS, Rode F, Rahbek M, Andersson KE, Rønn LC, Bouchelouche K, Nordling J, Bouchelouche P. Effect of the SK/IK channel modulator 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591) on contractile force in rat, pig and human detrusor smooth muscle. BJU Int. 2011 Sep; 108(5):771-7.
    View in: PubMed
    Score: 0.005
  147. Abdel-Hamid IA, Andersson KE, Salonia A. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories. Expert Opin Ther Targets. 2011 Mar; 15(3):325-40.
    View in: PubMed
    Score: 0.005
  148. Thüroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schröder A, Tubaro A. EAU guidelines on urinary incontinence. Eur Urol. 2011 Mar; 59(3):387-400.
    View in: PubMed
    Score: 0.005
  149. Strittmatter F, Gratzke C, Weinhold P, Steib CJ, Hartmann AC, Schlenker B, Andersson KE, Hedlund P, Stief CG, Hennenberg M. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol. 2011 Jan 15; 650(2-3):650-5.
    View in: PubMed
    Score: 0.005
  150. Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS. ß-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010 Nov; 342(2):295-306.
    View in: PubMed
    Score: 0.004
  151. Burnett AL, Goldstein I, Andersson KE, Argiolas A, Christ G, Park K, Xin ZC. Future sexual medicine physiological treatment targets. J Sex Med. 2010 Oct; 7(10):3269-304.
    View in: PubMed
    Score: 0.004
  152. Burmeister D, Aboushwareb T, Tan J, Link K, Andersson KE, Christ G. Early stages of in situ bladder regeneration in a rodent model. Tissue Eng Part A. 2010 Aug; 16(8):2541-51.
    View in: PubMed
    Score: 0.004
  153. Weinhold P, Gratzke C, Streng T, Stief C, Andersson KE, Hedlund P. TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation. J Urol. 2010 May; 183(5):2070-6.
    View in: PubMed
    Score: 0.004
  154. Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, Simonsen U, Uckert S, Wespes E, Andersson KE, Lue TF, Stief CG. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010 Jan; 7(1 Pt 2):445-75.
    View in: PubMed
    Score: 0.004
  155. Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson KE, Hedlund P. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010 May; 57(5):902-10.
    View in: PubMed
    Score: 0.004
  156. Gratzke C, Christ GJ, Stief CG, Andersson KE, Hedlund P. Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol. 2010 Feb; 57(2):342-8.
    View in: PubMed
    Score: 0.004
  157. Christ GJ, Andersson KE, Williams K, Zhao W, D'Agostino R, Kaplan J, Aboushwareb T, Yoo J, Calenda G, Davies KP, Sellers RS, Melman A. Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol. 2009 Dec; 56(6):1055-66.
    View in: PubMed
    Score: 0.004
  158. Zhang Y, McNeill E, Tian H, Soker S, Andersson KE, Yoo JJ, Atala A. Urine derived cells are a potential source for urological tissue reconstruction. J Urol. 2008 Nov; 180(5):2226-33.
    View in: PubMed
    Score: 0.004
  159. Delo DM, Eberli D, Williams JK, Andersson KE, Atala A, Soker S. Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. BJU Int. 2008 Sep; 102(7):878-84.
    View in: PubMed
    Score: 0.004
  160. Gratzke C, Streng T, Waldkirch E, Sigl K, Stief C, Andersson KE, Hedlund P. Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region. Eur Urol. 2009 Mar; 55(3):696-704.
    View in: PubMed
    Score: 0.004
  161. Hipp J, Andersson KE, Kwon TG, Kwak EK, Yoo J, Atala A. Microarray analysis of exstrophic human bladder smooth muscle. BJU Int. 2008 Jan; 101(1):100-5.
    View in: PubMed
    Score: 0.004
  162. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007 Mar 15; 67(6):2773-82.
    View in: PubMed
    Score: 0.003
  163. Christ G, Andersson KE, Atala A. The future of bladder research: molecular profiling, new drug targets, gene therapy, and tissue engineering. Curr Urol Rep. 2007 Mar; 8(2):95-9.
    View in: PubMed
    Score: 0.003
  164. Waldkirch ES, Uckert S, Langnäse K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol. 2007 Aug; 52(2):495-501.
    View in: PubMed
    Score: 0.003
  165. Albrecht K, Uckert S, Oelke M, Andersson KE, Jonas U, Tröger HD, Hedlund P. Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: a potential forensic value? J Forensic Leg Med. 2007 Jul; 14(5):270-4.
    View in: PubMed
    Score: 0.003
  166. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006 Sep; 98(3):503-7.
    View in: PubMed
    Score: 0.003
  167. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006 Dec; 50(6):1194-207; discussion 1207.
    View in: PubMed
    Score: 0.003
  168. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006 Jul; 148(5):565-78.
    View in: PubMed
    Score: 0.003
  169. Tolmachev V, Nilsson FY, Widström C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006 May; 47(5):846-53.
    View in: PubMed
    Score: 0.003
  170. Oelke M, Hedlund P, Albrecht K, Ellinghaus P, Stief CG, Jonas U, Andersson KE, Uckert S. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study. Urology. 2006 May; 67(5):1111-6.
    View in: PubMed
    Score: 0.003
  171. Werkström V, Svensson A, Andersson KE, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int. 2006 Aug; 98(2):414-23.
    View in: PubMed
    Score: 0.003
  172. Waldkirch E, Uckert S, Yildirim H, Sohn M, Jonas U, Stief CG, Andersson KE, Hedlund P. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance. World J Urol. 2005 Dec; 23(6):405-10.
    View in: PubMed
    Score: 0.003
  173. Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1457-62.
    View in: PubMed
    Score: 0.003
  174. Yoshimura N, Chancellor MB, Andersson KE, Christ GJ. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 2005 Apr; 95(6):733-8.
    View in: PubMed
    Score: 0.003
  175. Uckert S, Oelke M, Waldkirch E, Stief CG, Albrecht K, Tröger HD, Jonas U, Andersson KE, Hedlund P. Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves. Urology. 2005 Mar; 65(3):604-10.
    View in: PubMed
    Score: 0.003
  176. Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB, Marini M, Gelmini S, Fibbi B, Donati S, Villari D, Forti G, Colli E, Andersson KE, Maggi M. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab. 2005 Feb; 90(2):962-72.
    View in: PubMed
    Score: 0.003
  177. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004 Jul; 1(1):6-23.
    View in: PubMed
    Score: 0.003
  178. Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, Donnelly-Roberts DL, Nakane M, Lynch JJ, Kolasa T, Polakowski JS, Osinski MA, Marsh K, Andersson KE, Sullivan JP. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 Apr 27; 101(17):6758-63.
    View in: PubMed
    Score: 0.003
  179. Uckert S, Hedlund P, Waldkirch E, Sohn M, Jonas U, Andersson KE, Stief CG. Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol. 2004 Oct; 22(4):261-6.
    View in: PubMed
    Score: 0.003
  180. Nehra A, Steers WD, Althof SE, Andersson KE, Burnett AL, Costabile RA, Goldstein I, Kloner RA, Lue TF, Morales A, Rosen RC, Shabsigh R, Siroky MB, King L. Third International Conference on the Management of Erectile Dysfunction: Linking Pathophysiology and Therapeutic Response. J Urol. 2003 Aug; 170(2 Pt 2):S3-5.
    View in: PubMed
    Score: 0.003
  181. Drake MJ, Hedlund P, Andersson KE, Brading AF, Hussain I, Fowler C, Landon DN. Morphology, phenotype and ultrastructure of fibroblastic cells from normal and neuropathic human detrusor: absence of myofibroblast characteristics. J Urol. 2003 Apr; 169(4):1573-6.
    View in: PubMed
    Score: 0.003
  182. Staskin DR, Wein AJ, Andersson KE, Bauer SB, Blaivas JG, Burgio KL, Cardozo L, Chapple CR, Dmochowski RR, Gupta S, Mostwin JL, Ouslander JG, Weiss JP, King L. Overview consensus statement. Urology. 2002 Nov; 60(5 Suppl 1):1-6.
    View in: PubMed
    Score: 0.003
  183. Küthe A, Montorsi F, Andersson KE, Stief CG. Phosphodiesterase inhibitors for the treatment of erectile dysfunction. Curr Opin Investig Drugs. 2002 Oct; 3(10):1489-95.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.